Background: Hemolytic uremic syndrome related to Shiga-toxin-secreting Escherichia coli infection (STEC-HUS) remains a common cause of acute kidney injury in young children. No specific treatment has been validated for this severe disease. Recently, experimental studies highlight the potential role of complement in STEC-HUS pathophysiology. Eculizumab (EC), a monoclonal antibody against terminal complement complex, has been used in severe STEC-HUS patients, mostly during the 2011 German outbreak, with conflicting results.
Methods: On behalf of the French Society of Pediatric Nephrology, we retrospectively studied 33 children from 15 centers treated with EC for severe STEC-HUS. Indication for EC was neurologic involvement in 20 patients, cardiac and neurologic involvement in 8, cardiac involvement in 2, and digestive involvement in 3. Based on medical status at last follow-up, patients were divided into two groups: favorable (n = 15) and unfavorable outcomes (n = 18).
Results: Among patients with favorable outcome, 11/14 patients (79%) displayed persistent blockade of complement activity before each EC reinjection. Conversely, in patients with unfavorable outcome, only 9/15 (53%) had persistent blockade (p = n.s.). Among 28 patients presenting neurological symptoms, 19 had favorable neurological outcome including 17 with prompt recovery following first EC injection. Only two adverse effects potentially related to EC treatment were reported.
Conclusions: Taken together, these results may support EC use in severe STEC-HUS patients, especially those presenting severe neurological symptoms. The study, however, is limited by absence of a control group and use of multiple therapeutic interventions in treatment groups. Thus, prospective, controlled trials should be undertaken.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00467-018-3903-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A novel scoring system for the prediction of disease severity in STEC-HUS.
Pediatr Int
December 2024
Department of Pediatrics, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Background: Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is a life-threatening condition complicated by acute kidney injury, acute respiratory distress syndrome, and central nervous system disorders. The early identification of high-risk patients is required to facilitate timely and appropriate treatment.
Methods: The medical records of patients with STEC-HUS treated at 11 hospitals in Hokkaido, Japan, were reviewed retrospectively.
[Thrombotic microangiopathy as a rare complication after lung transplantation].
Praxis (Bern 1994)
October 2024
Klinik für Pneumologie, Universitätsspital Zürich, Rämistrasse 100, CH-8091 Zürich.
Thrombotic microangiopathy (TMA) is defined by the typical triad of severe thrombocytopenia, hemolytic anemia and endorgan dysfunction and can be characterized by the pathophysiology of ischemia-inducing microthrombi in arterioles and capillaries possibly leading to severe organ dysfunction up to acutely life-threatening endorgan damage. In terms of etiology, management, therapy and prognosis, the following manifestations are distinguished: thrombotic thrombocytopenic purpura (TTP), shigatoxin-induced hemolytic-uremic syndrome (STEC-HUS), secondary comorbidity-related TMA and atypical hemolytic-uremic syndrome (aHUS). We present the case of a 49 year old lung transplant recipient developing aHUS.
View Article and Find Full Text PDFOpen-label, controlled, phase 2 clinical trial assessing the safety, efficacy, and pharmacokinetics of INM004 in pediatric patients with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome.
Pediatr Nephrol
November 2024
Inmunova SA, Ciudad Autónoma de Buenos Aires, Argentina.
Background: Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome (STEC-HUS) is a severe condition mainly affecting children. It is one of the leading causes of acute kidney injury in the pediatric population. There is no established therapy for this disease.
View Article and Find Full Text PDFThe Role of the N-Terminal Domain of Thrombomodulin and the Potential of Recombinant Human Thrombomodulin as a Therapeutic Intervention for Shiga Toxin-Induced Hemolytic-Uremic Syndrome.
Toxins (Basel)
September 2024
Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, 07747 Jena, Germany.
Article Synopsis
- Hemolytic-uremic syndrome (HUS) is a serious condition that can happen after an infection and leads to kidney problems and low blood platelets.
- Researchers studied how a protein called thrombomodulin (TM) might affect HUS using mice, finding that mice without a part of TM were more affected by the infection.
- Although some reports suggest that a version of TM could help, experiments showed it didn't improve conditions in the mice, meaning more research is needed to understand TM’s role in treating HUS.
IgG-immunoadsorptions and eculizumab combination in STEC-hemolytic and uremic syndrome pediatric patients with neurological involvement.
Pediatr Nephrol
February 2025
Pediatric Nephrology, Dialysis and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France.
Article Synopsis
- * A retrospective study analyzed 42 pediatric patients treated with either IgIA + ECZ or ECZ alone, alongside a historical cohort receiving supportive care, with focus on survival and neurological outcomes after one year.
- * Results showed no significant survival difference between treatment groups; however, combining IgIA and ECZ did not demonstrate overall benefits for neurological outcomes, suggesting that this combination may only
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!